This developing technology will allow patients to regrow tissues in their own body, possibly revolutionizing the transplant market.
Morphoceuticals, Inc.’s mission is to establish a basis for limb regeneration and discovery of novel regenerative interventions.
Morphoceuticals originated from the work of Dr. Michael Levin, PhD
at the Allen Discovery Center at Tufts University. Our focus is on a revolutionary understanding of the biophysical mechanisms that implement decision-making during complex pattern regulation. We use bioelectric dynamics to change developmental patterning and spur regeneration in organisms that do not regenerate tissues or organs.
The team is building a next-generation AI platform to map top-down control of pattern regulation. Levin’s lab has been able to cause limb regeneration in a variety of animals. Morphoceuticals is initiating research to translate this progress from lower animals to mammals.
The frontier of regenerative medicine is a promising market that, estimated at $23 billion in 2018, is expected to increase to $150 billion by 2026.
We are here to help answer any questions you might have.